Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/22221751.2020.1780953 http://scihub22266oqcxt.onion/10.1080/22221751.2020.1780953 32529952!7473193!32529952     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Emerg+Microbes+Infect 2020 ; 9 (1): 1418-1428 Nephropedia Template TP {{tp|p=32529952|t=2020. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists |pdf=|usr=}}{{32529952}} gab.com Text SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists JO: Emerg Microbes Infect http://www.kidney.de/pget.php?&tw=1&pmid=32529952 #FOAvip The Coronavirus disease 2019 (COVID-19), which is caused by the novel SARS-CoV-2 virus, is now causing a tremendous global health concern. Since its first appearance in December 2019, the outbreak has already caused over 5.8 million infections worldwide (till 29 May 2020), with more than 0.35 million deaths. Early virus-mediated immune suppression is believed to be one of the unique characteristics of SARS-CoV-2 infection and contributes at least partially to the viral pathogenesis. In this study, we identified the key viral interferon antagonists of SARS-CoV-2 and compared them with two well-characterized SARS-CoV interferon antagonists, PLpro and orf6. Here we demonstrated that the SARS-CoV-2 nsp13, nsp14, nsp15 and orf6, but not the unique orf8, could potently suppress primary interferon production and interferon signalling. Although SARS-CoV PLpro has been well-characterized for its potent interferon-antagonizing, deubiquitinase and protease activities, SARS-CoV-2 PLpro, despite sharing high amino acid sequence similarity with SARS-CoV, loses both interferon-antagonising and deubiquitinase activities. Among the 27 viral proteins, SARS-CoV-2 orf6 demonstrated the strongest suppression on both primary interferon production and interferon signalling. Orf6-deleted SARS-CoV-2 may be considered for the development of intranasal live-but-attenuated vaccine against COVID-19. Twit Text FOAVip SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists ????Emerg Microbes Infect http://www.kidney.de/pget.php?&tw=1&pmid=32529952 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32529952 #FOAvip English Wikipedia <ref>{{Cite pmid|32529952}}</ref> SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists #MMPMID32529952 Yuen CK; Lam JY; Wong WM; Mak LF; Wang X; Chu H; Cai JP; Jin DY; To KK; Chan JF; Yuen KY; Kok KH Emerg Microbes Infect 2020[Dec]; 9 (1): 1418-1428 PMID32529952show ga The Coronavirus disease 2019 (COVID-19), which is caused by the novel SARS-CoV-2 virus, is now causing a tremendous global health concern. Since its first appearance in December 2019, the outbreak has already caused over 5.8 million infections worldwide (till 29 May 2020), with more than 0.35 million deaths. Early virus-mediated immune suppression is believed to be one of the unique characteristics of SARS-CoV-2 infection and contributes at least partially to the viral pathogenesis. In this study, we identified the key viral interferon antagonists of SARS-CoV-2 and compared them with two well-characterized SARS-CoV interferon antagonists, PLpro and orf6. Here we demonstrated that the SARS-CoV-2 nsp13, nsp14, nsp15 and orf6, but not the unique orf8, could potently suppress primary interferon production and interferon signalling. Although SARS-CoV PLpro has been well-characterized for its potent interferon-antagonizing, deubiquitinase and protease activities, SARS-CoV-2 PLpro, despite sharing high amino acid sequence similarity with SARS-CoV, loses both interferon-antagonising and deubiquitinase activities. Among the 27 viral proteins, SARS-CoV-2 orf6 demonstrated the strongest suppression on both primary interferon production and interferon signalling. Orf6-deleted SARS-CoV-2 may be considered for the development of intranasal live-but-attenuated vaccine against COVID-19. |Betacoronavirus/genetics/*metabolism[MESH] |COVID-19[MESH] |Cell Line[MESH] |Coronavirus Infections/genetics/*metabolism/virology[MESH] |Endoribonucleases/genetics/*metabolism[MESH] |Exoribonucleases/genetics/*metabolism[MESH] |Host-Pathogen Interactions[MESH] |Humans[MESH] |Interferons/*antagonists & inhibitors/genetics/*metabolism[MESH] |Methyltransferases/genetics/*metabolism[MESH] |Pandemics[MESH] |Pneumonia, Viral/genetics/*metabolism/virology[MESH] |RNA Helicases/genetics/*metabolism[MESH] |SARS-CoV-2[MESH] |Viral Nonstructural Proteins/genetics/*metabolism[MESH]SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon (epmc).pdf DeepDyve Pubget Overpricing